Talazoparib (Talzenna)

Mechanism of action

PARP inhibitor

Diseases for which it is used

• BRCA-mutated breast cancer

History of changes in FDA indication

• 10/16/2018: Initial approval for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer. (Based on EMBRACA)

Also known as

• Code name: BMN-673
• Brand name: Talzenna